Please login to the form below

Not currently logged in
Email:
Password:

Roche ends pursuit of gene sequencing company Illumina

Says chairman Franz Humer following failed $6.8bn bid

Roche Basel

Roche chairman Franz Humer told a German newspaper over the weekend that it has decided not to pursue a takeover of US gene sequencing company Illumina, despite rumours to the contrary.

Humer told the SonntagsZeitung that  Illumina deal was "nice to have" rather than a "must have" for Roche's diagnostics division and that it would definitely not be coming back to the bidding table having had an earlier $6.8bn offer rebuffed last year.

Roche called off the $51-per-share hostile takeover bid last April after shareholders in the gene sequencing specialist re-elected directors onto the board who were opposed to the deal.

Humer said Illumina was "not willing to abandon the totally unrealistic price they were asking for" and reiterated that there are other companies around with rival technology platforms that may be of interest for Roche.

The company said last year that lower-cost sequencing technology from firms such as Life Technologies and Oxford Nanopore Technologies could eventually knock Illumina off the top of the gene sequencing market.

Since then Illumina added to its technology portfolio with the acquisition of cytogenetics and in vitro fertilisation/pre-implantation genetic testing specialist BlueGnome, and said in its third-quarter results statement that revenues has risen more than 20 per cent "due to the strength of our sequencing business", although growth in sequencing is said to be slowing.

Illumina has said it intends to expand into new clinical diagnostic areas, such as personalised medicine and cancer diagnostics, that could double the potential market targeted by its products to around $8bn worldwide.

Humer also said in the interview that Roche chief executive Severin Schwan will not succeed him as company chairman, as the company will not return to a situation where the same individual holds both roles.

7th January 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Free White Paper: Customer Experience for Pharma
To learn why an effective customer experience strategy is vital for pharma, download our white paper “Customer experience for pharma” to learn more....
How ethical is your brand plan? Introducing the hEQ.
Assess your brand plan’s Healthcare Ethics Quotient and see how these questions can give your brand plan a new perspective and engage your internal teams and external customers....
solution_options.png
Why e-detailing must give options to healthcare professionals
We know, we know. You want to talk about your treatment right away, but this really is an essential step that will make your e-detailing even more credible....